Transcutaneous Auricular Vagus Nerve Stimulation Added to Physiotherapy for Adhesive Capsulitis (taVNS-AC)
Effect of Transcutaneous Auricular Vagus Nerve Stimulation Added to Standard Physiotherapy on Pain, Function, and Quality of Life in Patients With Shoulder Adhesive Capsulitis: A Randomized Controlled Trial
This randomized, sham-controlled study will evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS), when added to standard physiotherapy, improves pain, shoulder function, range of motion, and quality of life in adults with adhesive capsulitis.
A total of 40 participants aged 18 to 65 years will be randomly assigned to one of two groups. Both groups will receive 15 sessions of standard physiotherapy over 3 weeks. In addition, one group will receive active taVNS for 30 minutes per day, while the other group will receive sham stimulation for the same duration and frequency. Assessments will be performed before treatment and after the 15th treatment session using pain, shoulder disability, quality-of-life, and shoulder range-of-motion measurements.
研究概览
地位
条件
详细说明
Adhesive capsulitis is a musculoskeletal condition characterized by shoulder pain and progressive restriction of active and passive range of motion. Although physiotherapy, therapeutic exercise, and manual therapy are commonly used, pain relief and functional recovery may be incomplete in some patients. Therefore, additional non-invasive treatment approaches that may enhance the effects of rehabilitation are clinically relevant.
Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve. It may influence pain modulation, autonomic nervous system regulation, and inflammatory pathways. Previous studies have reported potential benefits of auricular vagus nerve stimulation in several chronic pain conditions; however, evidence regarding its use in adhesive capsulitis remains limited.
The objective of this study is to determine whether active taVNS added to standard physiotherapy provides greater clinical improvement than sham taVNS added to the same physiotherapy program. The main hypothesis is that participants receiving active taVNS will demonstrate greater reductions in pain and shoulder-related disability after treatment. Secondary objectives are to evaluate changes in shoulder range of motion and health-related quality of life and to assess the tolerability of the intervention.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Muhsin Doran, MD
- 电话号码:05340807940
- 邮箱:muhsin-doran@hotmail.com
学习地点
-
-
Istanbul
-
Istanbul、Istanbul、土耳其(türkiye)、34381
- 招聘中
- Liv hospital Vadistanbul
-
接触:
- Muhsin Doran, MD
- 电话号码:05340807940
- 邮箱:muhsin-doran@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age between 18 and 65 years.
- Clinical diagnosis of adhesive capsulitis confirmed by physical examination and, when clinically indicated, imaging.
- Shoulder pain and limitation of shoulder range of motion for at least 3 months.
- Provision of written informed consent.
- General health status sufficient to participate in standard physiotherapy and active or sham transcutaneous auricular vagus nerve stimulation.
- Ability to comply with the planned treatment sessions and outcome assessments.
Exclusion Criteria:
- Shoulder stiffness secondary to trauma, surgery, infection, or tumor.
- Rotator cuff tear, advanced glenohumeral osteoarthritis, or inflammatory rheumatic disease.
- Glucocorticoid injection into the affected shoulder within the previous 3 months.
- Surgical intervention involving the affected shoulder within the previous 6 months.
- Active infection or skin lesion in the shoulder region.
- Cervical radiculopathy, brachial plexopathy, stroke, or another neurological disorder affecting the upper extremity.
- Presence of a cardiac pacemaker or another implanted electronic device.
- Pregnancy or breastfeeding.
- Serious systemic disease or cognitive impairment that may prevent compliance with the study protocol.
- Known intolerance or previous adverse reaction to transcutaneous electrical stimulation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Standard Physiotherapy Plus Active taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks.
Active transcutaneous auricular vagus nerve stimulation is administered for 30 minutes during each treatment session in addition to the physiotherapy program.
|
Active transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy.
Electrical stimulation will be delivered transcutaneously through an auricular electrode to a vagally innervated region of the external ear.
The physiotherapist administering the stimulation will be aware of group allocation, while participants and the outcomes assessor will remain blinded.
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week.
The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles.
Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations.
The same physiotherapy protocol will be administered to both study arms.
|
|
假比较器:Standard Physiotherapy Plus Sham taVNS
Participants receive 15 sessions of standard physiotherapy over 3 weeks.
In addition, sham transcutaneous auricular vagus nerve stimulation is administered for 30 minutes with the same frequency and treatment schedule as the active stimulation.
|
Participants will receive 15 standard physiotherapy sessions over 3 weeks, with five sessions per week.
The program will include pain-relieving physical therapy modalities, glenohumeral and scapulothoracic joint mobilization, passive and active-assisted range-of-motion exercises, capsular stretching, and progressive strengthening exercises for the rotator cuff and scapular stabilizing muscles.
Treatment intensity and exercise progression will be individualized according to pain severity, irritability, and range-of-motion limitations.
The same physiotherapy protocol will be administered to both study arms.
Sham transcutaneous auricular vagus nerve stimulation will be administered for 30 minutes per session during each of 15 treatment sessions over 3 weeks, in addition to standard physiotherapy.
The sham procedure will follow the same session frequency and duration as the active intervention but will be applied according to a prespecified sham protocol that is not expected to produce therapeutic vagal stimulation.
The physiotherapist administering the intervention will be aware of group allocation, while participants and the outcomes assessor will remain blinded.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Shoulder Pain and Disability Index (SPADI) Total Score
大体时间:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
The Shoulder Pain and Disability Index (SPADI) is a 13-item patient-reported questionnaire consisting of a 5-item pain subscale and an 8-item disability subscale.
The total score ranges from 0 to 100, with higher scores indicating greater shoulder pain and disability.
The primary outcome will be the change in the SPADI total score from baseline to the assessment performed after completion of the 15th treatment session.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Shoulder Pain Intensity Assessed With the Visual Analog Scale (VAS)
大体时间:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Shoulder pain intensity will be assessed using a 10-cm Visual Analog Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Higher scores indicate greater pain intensity.
The outcome will be calculated as the change in VAS score from baseline to the assessment performed after completion of the 15th treatment session.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
|
Change in Shoulder Flexion Range of Motion
大体时间:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Change in Shoulder Flexion Range of Motion Change in Shoulder Abduction Range of Motion Change in Shoulder Extension Range of Motion Change in Shoulder Internal Rotation Range of Motion Change in Shoulder External Rotation Range of Motion Change in Shoulder Horizontal External Rotation Range of Motion Change in Shoulder Horizontal Abduction Range of Motion Change in Shoulder Horizontal Adduction Range of Motion
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
|
Change in Health-Related Quality of Life Assessed With the 36-Item Short Form Health Survey (SF-36)
大体时间:Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36).
The questionnaire evaluates eight domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health.
Each domain is scored from 0 to 100, with higher scores indicating better health-related quality of life.
Changes in domain scores from baseline to the post-treatment assessment will be evaluated.
|
Baseline and immediately after completion of the 15th treatment session, approximately 3 weeks
|
合作者和调查者
赞助
调查人员
- 首席研究员:Muhsin Doran、Liv hospital Vadistanbul
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.